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Abstract: Approximately seventy percent of ovarian cancer patients succumb to the disease within the
first 5 years of diagnosis, even after successful surgery and effective chemotherapy treatment. A small
subset of chemotherapy resistant cancer stem cells (CSCs) cause relapse of ovarian cancers. This study
investigated the association between paclitaxel-mediated Src activation (p-Src) and CSC populations
in driving ovarian cancer progression. We demonstrate that patients with high-stage serous ovarian
carcinomas have significantly elevated levels of p-Src, compared to patient with low-stage and benign
ovarian tumours. Additionally, p-Src was significantly enhanced in ascites-derived tumour cells
obtained from recurrent patients, compared to chemonaïve patients. Paclitaxel treatment increased
Src activation in ovarian cancer cells, causing enrichment of CSC marker expression in the surviving
cells in vitro and in xenografts of nude mice. Dasatinib in combination with paclitaxel significantly
suppressed p-Src in ovarian cancer cell lines and xenografts but had no effect on the expression of
CSC markers. However, combination of paclitaxel and Dasatinib showed lower trend in invasion in
liver and pancreas, compared to paclitaxel-only treatment. The tumours treated with combination
therapy also had significantly lower infiltration of mononuclear cells. Robust recurrent tumour
growth was observed in all mice groups after termination of treatments. The above results suggest
that Dasatinib-mediated inhibition of p-Src may not be crucial for paclitaxel-induced CSC-mediated
recurrence in ovarian cancer.
Keywords: ovarian carcinoma; ascites; chemoresistance; chemotherapy; Dasatinib; paclitaxel; cancer
stem cells
1. Introduction
Every twelve hours one woman dies of ovarian cancer worldwide. The high mortality rate
in ovarian cancer patients results from the diagnosis of the disease at an advanced-stage when the
cancer has already spread into the peritoneal cavity [1]. The management of ovarian cancer patients
after debulking surgery involves systemic administration of platinum (cisplatin/carboplatin) and
taxane-based (paclitaxel) drugs [2]. This treatment regimen results in a significant reduction of tumour
burden due to substantial cancer cell death. Hence, approximately 80% of ovarian cancer patients
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respond to the initial standard treatment regimen and enjoy a short-lived period of remission with
asymptomatic minimal disease [3]. However, the microscopic residual disease persisting after the
first line chemotherapy usually gives rise to consecutive episodes of recurrent disease and eventual
death. Disappointingly, a five-year survival period of ovarian cancer patients has remained unchanged
and as low as ~30–40% for the last forty years [3]. Hence, there is an urgent need to identify and
target mechanisms, which allow surviving residual cancer cells to overcome the cytotoxic effects of the
chemotherapy and propagate within the changed tumour microenvironment.
Due to the anatomical positioning of the ovaries and minimal physical barriers, ovarian cancer
cells readily metastasize and colonise within the parietal and visceral peritoneum, including omentum,
diaphragm and small bowel mesentery [4]. This event is further augmented by the dedifferentiation
of cancer cells in the progressing tumour microenvironment, particularly after the exposure of
cytotoxic chemotherapy that imposes an inflammatory microenvironment [5]. The residual cells,
after chemotherapy treatment, emerge with cancer stem cell-like (CSC) characteristics and phenotypic
changes allowing them to propagate rapidly, overcoming apoptotic signals and immune regulation [5].
Furthermore, in the tumour microenvironment the stem-cell like cancer cells use self-modulated vessels
that support angiogenesis, further aiding tumour growth and cancer metastasis [6,7]. Hence, the
changes in the chemotherapy triggered microenvironment imposes alteration in signalling pathways
in chemotherapy resistant stem-cell like cancer cells, which ultimately drives the disease into relapse
and further consecutive episodes of recurrences [8,9].
Enhanced expression of Src kinase in cancers has been shown to deregulate cell cycle and cancer
cell survival [10,11]. In ovarian cancer, Src is expressed at late stages and in poorly differentiated
cancer cell lines [12,13]. In a panel of 119 ovarian tumours, patients identified as having dysregulation
in Src gene were found to have worst prognosis. Poor prognostic outcomes associated with increased
Src expression are attributed to its correlation with paclitaxel resistance. Inhibition of Src has been
shown to increase the sensitivity of ovarian cancer cells to paclitaxel treatment [13].
Recognising the clinical potential of Src targeting in improving disease outcomes, multi-kinase
inhibitor Dasatinib has been used to treat several malignancies in preclinical studies and clinical
trials. The use of Dasatinib was approved in 2006 by the Food and Drug Administration (FDA)
for the treatment of imatinib-resistant or intolerant adult chronic myeloid leukemia, Philadelphia
chromosome-positive acute myeloid or lymphoblastic leukemia [14]. Alongside the Src family kinases
(Src, Lck, Yes, and Fyn), this inhibitor targets BCR-ABL protein, stem cell factor receptor (c-Kit), EPH
receptor A2, and platelet-derived growth factor receptor (PDGFR)-β at nanomolar concentrations [15].
Screening of 34 human ovarian cancer cell lines revealed that high expression of Yes, Lyn, Eph2A,
caveolin-1 and 2, moesin, annexin-1, and uPA, and low expression of insulin-like growth factor-binding
protein 2 (IGFBP2) render the cells sensitive to Dasatinib treatment [16]. Additionally, co-treating
ovarian cancer cells with Dasatinib renders these cells sensitive to the cytotoxic effect of paclitaxel or
carboplatin based chemotherapeutic drugs [13,17].
The aim of this study was to evaluate the effect of Dasatinib on paclitaxel-induced CSC properties
in ovarian cancer cell lines in vitro and in an in vivo mouse model. The main aim was to evaluate
if treatment with Dasatinib in combination with paclitaxel may affect tumour burden, peritoneal
dissemination and disease-free remission period in a mouse model. We chose two ovarian cancer
cell lines representative of high-grade serous (HEY) and clear cell (TOV-21G) ovarian carcinomas
to determine the in vitro effect of paclitaxel with or without Dasatinib treatment. HEY cell line was
used to determine in the in vivo effect of paclitaxel with or without Dasatinib. For the first time, this
study provides insight on the Src-mediated survival aspects of chemotherapy-treated residual ovarian
CSCs, which trigger a recurrent disease. We demonstrate that, in mice Dasatinib in combination
with paclitaxel had no significant effect in reducing tumour burden over paclitaxel-alone treatment.
In addition, combination treatment had no effect on the CSC-like profile of mouse xenografts, nor did
it prolong overall survival in tumour-bearing mice once the treatment with paclitaxel and Dasatinib
was terminated. These results suggest that Dasatinib may be a good agent in reducing initial tumour
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burden but may not be an effective therapeutic for the better management of recurrent ovarian cancer
patients long-term.
2. Results
2.1. Active Src Levels Are Increased in the Primary Ovarian Tumours of High-Stage Serous Ovarian Cancer
Patients and in the Ascites-Derived Tumour Cells of Advanced-Stage Recurrent Patients
In this study, immunohistochemical analysis was performed to compare the expression of
phospho (p)-Src and total (t)-Src between normal/benign tissues, low and high-stage ovarian tumours
(Table 1). Eight ovarian tissues samples were obtained from non-ovarian carcinoma patients, which
consisted of two normal ovarian tissue samples from patients undergoing hysterectomy or bilateral
salpingo-oophorectomy due to pre-diagnosed medical conditions. Six benign ovarian tumour samples
were obtained from patients undergoing hysterectomy due to the presentation of cysts. Ovarian tissues
from serous ovarian cancer patients consisted of three low-stages (FIGO stage I) and ten advanced-stage
(FIGO stages III and IV) samples, collected at the time of primary ovarian cancer surgery (patient
details are summarized in Table 1).
The expression of p-Src was significantly greater in high-stage serous ovarian tumours, compared
to low-stage and benign ovarian tumours (Figure 1A,B). The level of expression and activation of
Src was assessed by immunofluorescence in non-adherent cell populations derived from ascites
of unmatched advanced-stage recurrent serous ovarian cancer patients, previously treated with
chemotherapy (n = 6) and advanced-stage chemonaïve serous ovarian cancer patients (n = 8) (Table 2).
Activated p-Src protein localized more in the nucleus in ascites-derived cells from recurrent patients,
compared to those who were chemonaïve (Figure 1C). The mean fluorescent intensity of p-Src relative
to t-Src was approximately 2-folds higher in chemotherapy-treated recurrent patients, compared to
chemonaïve patients (Figure 1D).
2.2. Src Activation Was Transiently Induced in Ovarian Cancer Cell Lines by Paclitaxel Treatment
To determine if the activation of Src can be upregulated in ovarian cancer cells in response to
chemotherapy and to mimic the profile seen in the ascites-derived tumour cells of chemotherapy treated
patients, the HEY ovarian cancer cell line was subjected to IC50 concentration of paclitaxel (0.05 µg/mL)
for 6, 24 and 72 h (Supplementary Figure S1). Src expression was assessed by immunofluorescence
and western blot analysis.
Immunofluorescent studies revealed that there was a nuclear translocation of p-Src from
cytoplasm starting at 6 h (Figure 2A). This was more evident at 24 and 72 h of paclitaxel treatment
(Figure 2B). However, the cytosolic expression of t-Src remained unchanged across all groups and time
points (Figure 2C).
Western blot analysis showed that in HEY cells treated with paclitaxel, p-Src protein levels were
significantly higher at 24 h compared to control, 6 and 72 h treatments (Figure 2D). The expression of
p-Src at 6 and 72 h after paclitaxel treatment remained similar to the untreated cells (Figure 2E). T-Src
expression remained unchanged between all groups (Figure 2F).
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Table 1. Description of patients recruited for immunohistochemistry expression of Src activation.
Sample
No. Diagnosis FIGO Stage
Age at
Diagnosis Genetic Background
Pre-Operative
CA125
Ascites at
Diagnosis Survival
Normal
1 Normal ovarian epithelium - BRCA+ - No -
2 Normal ovarian epithelium - Peutz-Jegher’s syndrome - No -
Benign
1 Benign cyst - 19 - - No -
2 Benign cyst - 55 - - No -
3 Large multi cysts ovarian mass - 64 Family history of Ca - No -
4 Benign cyst - 58 Diagnosed with breast cancer - No -
5 Large ovarian cyst - 62 Unknown - No -
6 Benign cyst - 48 HNPCC carrier (colorectal cancer) - No -
Low-Stage
1 Serous cystadenocarcinoma NOS (Gr3) Ic 90 Unknown 24 No 1 month ALC
2 Serous cystadenocarcinoma NOS Ia 36 Unknown 138 No 2 years 4 months ALC
3 Serous cystadenocarcinoma (Gr1) Ic 31 Unknown 177 No 4 years 10 months ALC
High-Stage
1 Papillary serous adenocarcinoma (Gr3) 55 - 3025 Yes 2 years 5 months at death
2 Serous cystadenocarcinoma NOS (Gr2) IIIc 65 Unknown 903 Yes 1 year 9 months at death
3 Carcinoma NOS (Gr3) III 62 BRCA+ 3058 Yes 2 years 7 months at death
4 Serous cystadenocarcinoma NOS (Gr3) IIIc 38 Unknown 957 Yes 2 years 8 months ALC
5 Serous surface papillary carcinoma (Gr3) IIIc 59 BRCA2+ 397 Yes 4 years 7 months at death
6 Papillary serous adenocarcinoma (Gr2) IIIc 41 Family history of ovarian cancer Unknown Unknown 8 years 8 months ALC
7 Serous cystadenocarcinoma NOS (Gr3) IIIc 67 Unknown Unknown Yes 9 months at death
8 Papillary serous adenocarcinoma (Gr2) IIIc 43 - 428 Yes 3 years 7 months at death
9 Papillary serous adenocarcinoma (Gr2) IV 58 Family history of uterine cancer 3187 Yes 6 years 10 months at death
10 Papillary serous adenocarcinoma (Gr3) IIIc 53 Unknown 1838 Yes 1 year 9 months at death
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Table 2. Description of chemonaïve and recurrent patients recruited for the collection of ascites-derived tumour cells.
Sample Classification Diagnosis Grade FIGO Stage Treatment Age at Diagnosis Survival
Chemonaïve Serous cystadenocarcinoma NOS G3- poorly differentiated IV None 76 7 months at death
Chemonaïve Serous cystadenocarcinoma NOS G3- poorly differentiated IIIc None 64 1 month at death
Chemonaïve Serous cystadenocarcinoma NOS G3- poorly differentiated IV None 83 1 year 10 months at death
Chemonaïve Serous cystadenocarcinoma NOS G3- poorly differentiated IIIc None 41 1 year 7 months ALC
Chemonaïve Serous cystadenocarcinoma NOS G3- poorly differentiated IIIc None 52 1 year 9 months ALC
Chemonaïve Carcinoma NOS G3- poorly differentiated IIc None 62 2 years 2 months ALC
Chemonaïve Serous cystadenocarcinoma NOS G3- poorly differentiated IIIc None 63 9 months ALC
Chemonaïve Adenocarcinoma NOS G3- poorly differentiated IV None 52 1 year ALC
Recurrent Serous cystadenocarcinoma NOS G3- poorly differentiated IV
Carboplatin and Paclitaxel 6 cycles
Carboplatin 4 cycles
Cisplatin 2 cycles
Doxorubicin Pegylated Liposomal 1 cycle
50 1 year 10 months at death
Recurrent Serous surface papillarycarcinoma (Gr3) G3- poorly differentiated IIIc
ICON6 Trial 8 cycles
Carboplatin and Paclitaxel 6 cycles
OVAR16/VEG110655 Trial 4 cycles
Cisplatin 6 cycles
Doxorubicin Pegylated Liposomal 6 cycles
Docetaxel 3 cycles
REZOLVE Study 3 cycles
Paclitaxel 1 cycl
59 4 years 7 months at death
Recurrent Serous cystadenocarcinoma NOS(Gr3) G3- poorly differentiated IV
REZOLVE Study 5 cycles Unspecified Regimen
7 cycles Doxorubicin Pegylated Liposomal 6 cycles
Paclitaxel 5 cycles Cisplatin 6 cycles
57 5 years 8 months at death
Recurrent Serous cystadenocarcinoma NOS(Gr3) G3- poorly differentiated IIIc
Carboplatin and Paclitaxel 6 cycles
PrePARE Study 2 cycles
Cisplatin 5 cycles
Unspecified Regimen 6 cycles
Doxorubicin Pegylated Liposomal 5 cycles
61 2 years 2 months at death
Recurrent Papillary serous adenocarcinoma(Gr2) G1- well differentiated IIIc
Carboplatin and Paclitaxel 3 cycles Doxorubicin
Pegylated Liposomal 4 cycles 31 9 months at death
Recurrent Papillary serous adenocarcinoma(Gr2) G3- poorly differentiated IIc
Carboplatin and Paclitaxel 6 cycles
Lilly Trial 3 cycles
Cisplatin 1 cycle
Doxorubicin Pegylated Liposomal 3 cycles
Paclitaxel 2 cycles
REZOLVE Study 1 cycle
68 6 years 1 month at death
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Figure 1. Late-stage and chemotherapy treated ovarian cancer patient samples have greater level of 
p-Src than early-stage and chemonaïve patients. (A) Representative images of p-Src and t-Src 
staining in primary ovarian benign tumours, FIGO stage I (low-stage) and III/IV (high-stage) serous 
ovarian cancer patients. Magnification 200× scale bar = 200 µM and 400× scale bar = 60 µM. (B) 
Quantification of p-Src and t-Src DAB staining was performed using Fiji software. Results are 
displayed as overall average DAB reading of p-Src relative to t-Src of the same samples ± SEM. (C) 
Expression and localization of the Src pathway activation was evaluated by immunofluorescence in 
non-adherent tumour cells derived from the ascites of chemonaïve and chemotreated recurrent 
serous ovarian cancer patients. Staining was visualized using the secondary Alexa 590 (red) and 
nuclei were detected by DAPI (blue) staining. Images are representative of n = 8 chemonaïve and n = 
6 chemo-treated ascites-derived cells. Magnification 400× scale bar = 250 µM. (D) Quantification of 
t-Src and p-Src fluorescent intensities was determined using Fiji software. Results are displayed as 
average fluorescent intensity value of p-Src relative to t-Src of the same ascites sample ± SEM. 
Significance is indicated by * p < 0.05, ** p < 0.01. 
 
Figure 1. Late-stage and chemotherapy treated ovarian cancer patient samples have greater level of
p-Src than early-stage and chemonaïve patients. (A) Representative images of p-Src and t-Src staining
in primary ovarian benign tumours, FIGO stage I (low-stage) and III/IV (high-stage) serous ovarian
cancer patients. Magnification 200× scale bar = 200 µM and 400× scale bar = 60 µM. (B) Quantification
of p-Src and t-Src DAB staining was performed using Fiji software. Results are displayed as overall
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average DAB reading of p-Src relative to t-Src of the same samples ± SEM. (C) Expression and
localization of the Src pathway activation was evaluated by immunofluorescence in non-adherent
tumour cells derived from the ascites of chemonaïve and chemotreated recurrent serous ovarian
cancer patients. Staining was visualized using the secondary Alexa 590 (red) and nuclei were detected
by DAPI (blue) staining. Images are representative of n = 8 chemonaïve and n = 6 chemo-treated
ascites-derived cells. Magnification 400× scale bar = 250 µM. (D) Quantification of t-Src and p-Src
fluorescent intensities was determined using Fiji software. Results are displayed as average fluorescent
intensity value of p-Src relative to t-Src of the same ascites sample ± SEM. Significance is indicated by
* p < 0.05, ** p < 0.01.
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Figure 2. Exposure of HEY cells to paclitaxel enhances phosphorylation of Src in a time dependent 
manner. (A) The expression of p-Src and t-Src was assessed by immunofluorescence in untreated 
and paclitaxel (0.05 µg/mL) treated cells following 6, 24 or 72 h of incubation. Staining was 
visualized using the secondary Alexa 590 (red) fluorescent-labelled antibody, and nuclei were 
detected by DAPI (blue) staining. Magnification 400× scale bar = 250 µm. Quantification of (B) p-Src 
and (C) t-Src fluorescent intensities were conducted using Fiji software. Results are displayed as the 
percentage of the average fluorescent intensity relative to untreated cells ± SEM (n = 3/group). (D) 
Total cell lysates of HEY cells were collected at 6, 24 and 72 h after paclitaxel treatment and were 
subjected to immunoblot analysis using antibodies specific for p- or t-Src or GAPDH. Images are 
representative of three independent experiments. Densitometry analysis of (E) p-Src and (F) t-Src 
protein expressions. The values represent the relative mean of band intensity normalized to 
GAPDH loading control ± SEM. Significance is indicated by * p < 0.05, ** p < 0.01. 
The patterns of p-Src expression in response to paclitaxel in TOV-21G cells showed Src 
activation within 24 h by immunofluorescence which diminished at 72 h (Supplementary Figures 
S2A,B). However, western blot analysis revealed sustenance of that activation by the 72 h time point 
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Figure 2. Exposure of HEY cells to paclitaxel enhances phosphorylation of Src in a time dependent
manner. (A) The expression of p-Src and t-Src was assessed by immunofluorescence in untreated and
paclitaxel (0.05 µg/mL) treated cells following 6, 24 or 72 h of incubation. Staining was visualized using
the secondary Alexa 590 (red) fluorescent-labelled antibody, and nuclei were detected by DAPI (blue)
staining. Magnification 400× scale bar = 250 µm. Quantification of (B) p-Src and (C) t-Src fluorescent
intensities were conducted using Fiji software. Results are displayed as the percentage of the average
fluorescent intensity relative to untreated cells ± SEM (n = 3/group). (D) Total cell lysates of HEY cells
were collected at 6, 24 and 72 h after paclitaxel treatment and were subjected to immunoblot analysis
using antibodies specific for p- or t-Src or GAPDH. Images are representative of three independent
experiments. Densitometry analysis of (E) p-Src and (F) t-Src protein expressions. The values represent
the relative mean of band intensity normalized to GAPDH loading control ± SEM. Significance is
indicated by * p < 0.05, ** p < 0.01.
The patterns of p-Src expression in response to paclitaxel in TOV-21G cells showed Src
activation within 24 h by immunofluorescence which diminished at 72 h (Supplementary
Figure S2A,B). However, western bl t analysis revealed suste ance of that activation by the 72 h
time point (Supplementary Figure S2D,E). T-Src expressio remained unchanged between all grou s
(Supplementary Figure S2C,F).
2.3. The Addition of Dasatinib Suppressed Paclitaxel-Induced Src Activation in Ovarian Cancer Cells
Immunofluorescence was used to investigate the effect of Dasatinib on inhibiting Src activation in
HEY cells, when given alone (10 µM) and in combination with paclitaxel (0.05 µg/mL) (Supplementary
Figures S1 and S3).
Enhanced intensity of nuclear localisation of p-Src was evident in paclitaxel treated cells compared
to control untreated cells (Figure 3A). Quantification of the fluorescent intensity of p-Src proteins
showed significant greater levels of activated protein in the paclitaxel treated cells, compared to the
untreated group (Figure 3B). Dasatinib treated cells had a similar intensity of p-Src as untreated cells,
which was significantly lower than the cells treated with paclitaxel. In addition, the combination
of Dasatinib with paclitaxel significantly inhibited p-Src compared to paclitaxel-only treated groups
(Figure 3A,B). There was no significant difference in the expression of t-Src between control and
treatment groups (Figure 3C).
These results were consistent in the ovarian cancer TOV-21G cell line which showed a significant
elevation of p-Src in response to paclitaxel treatment which was abolished by Dasatinib treatment
(Supplementary Figure S4A,B). No significant difference in the expression of t-Src and between control
and treatment groups was also observed (Supplementary Figure S4C).
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Figure 3. Dasatinib inhibits paclitaxel-induced Src activation in HEY cells. (A) Immunofluorescent
visualization of expression and localization of the p- or t-Src proteins in untreated HEY cells or
following a 24 h treatment with paclitaxel (0.05 µg/mL), Dasatinib (10 µM) or a combination of both.
Staining was visualized using the secondary Alexa 590 (red) fluorescent-labelled antibodies and nuclei
were detected by DAPI (blue) staining. Images are representative of three independent experiments.
Magnification 400× scale bar = 250 µm. Quantification of (B) p-Src and (C) t-Src fluorescent intensities
were determined using Fiji software. Results are expressed as the percentage of the average fluorescent
intensity value relative to untreated cells ± SEM (n = 3/group). Significance between the groups and is
indicated by * p < 0.05, ** p < 0.01.
2.4. Dasatinib Reduced Some Paclitaxel-Induced CSC-Like Marker Expression in Ovarian Cancer Cells
The effect of Dasatinib on paclitaxel-induced CSC-like marker expression of ovarian cancer cells
was analysed using flow cytometry. The expression of the markers EpCAM, CD44, CD133 and SSEA-4
were analysed by subjecting HEY cells to IC50 concentrations of paclitaxel (0.05 µg/mL), Dasatinib
(10 µM) and a combination of both.
Paclitaxel significantly enhanced the expression of EpCAM in HEY ovarian cancer cell line
and it was significantly suppressed by the addition of Dasatinib (Figure 4A,B). SSEA-4 and CD133
CSC-like markers were significantly upregulated by paclitaxel treatment. Even though Dasatinib
had a decreasing effect on the paclitaxel-induced expression of these markers it was not significant
(Figure 4C–F). Furthermore, there was an insignificant but increasing trend in the expression of CD44
in response to paclitaxel treatment. Dasatinib slightly decreased this effect on the expression of CD44
(Figure 4G,H).
On the other hand, paclitaxel induced significant upregulation in the expression of EpCAM,
and CD133, which was inhibited by Dasatinib in TOV-21G cell line (Supplementary Figure S5A–H).
The expression of SSEA-4 and CD44 had an increasing trend with paclitaxel treatment in TOV-21G
cells, which was decreased by Dasatinib without significance.
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2.5. Combination Treatment Had no Significant Effect in Reducing Tumour Burden Over Paclitaxel but
Inhibited Src Activation in HEY Derived Xenografts
To investigate the in vivo anti-tumourigenic effect following the administration of Dasatinib in
conjunction with paclitaxel, mice were killed at the 30-day endpoint (12-day of treatment) and their
tumour burden was measured. Similar to previously reported results [18], upon dissection, multiple
tumour deposits were observed in the liver, pancreas and bowels and several smaller tumour nodules
were found throughout the peritoneal cavity of control untreated mice. Mice treated with paclitaxel
or Dasatinib developed smaller tumour nodules and fewer tumours were found from each mouse
compared to control untreated mice. We compared the tumour burden between all mice in the study.
Untreated control mice developed the largest tumour burden compared to all groups (Figure 5A).
Significantly reduced tumour burden was observed in the group injected weekly with paclitaxel
compared to control mice. Mice treated with the combination of paclitaxel and Dasatinib also had
significantly smaller tumour burden compared to control animals, however, this was not significantly
different compared to paclitaxel-alone treated mice. Daily Dasatinib treatment reduced tumour burden
to similar levels observed in the paclitaxel treated mice, however, this was significantly larger than
mice treated with combination of the two drugs. Paclitaxel, Dasatinib or a combination of both were
well tolerated in mice without any major adverse effects. In line with in vitro results, the tumours
generated with paclitaxel alone treatment had significantly higher p-Src protein, which was inhibited
significantly by a combination of paclitaxel and Dasatinib treatments (Figure 5B,C). The p-Src levels
of combination treated xenografts were significantly lower than control and paclitaxel-alone treated
tumours (Figure 5C). The t-Src levels remained relatively unchanged between the experimental groups
(Figure 5D).
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2.6. Inhibition of p-Src by Dasatinib Had no Significant Effect on Paclitaxel-Induced Expression of CSC,
Proliferation, Tumourigenicity or the Vascularization Markers
Paclitaxel-treated tumours had a significantly greater percentage of Ki67 positive proliferating
cells than untreated control xenografts (Figure 6A,B). Despite the significantly less Ki67 positivity in
Dasatinib-alone treated tumours, the combined treatment group did not show a significant reduction
in the Ki67 positive cells compared to the paclitaxel-treated group (Figure 6A,B). Combination treated
tumours had significantly higher levels of Ki67 positivity than the Dasatinib alone treated groups.
CA125 is used as a predictive biomarker in ovarian cancer screening and monitoring. Treatment
with paclitaxel significantly upregulated the expression of CA125 in HEY xenografts (Figure 6A–C).
Treatment with Dasatinib had no effect on the expression of this marker compared to control untreated
xenografts. Combined treatment with paclitaxel and Dasatinib did not reduce the expression of CA125
compared to paclitaxel treatment alone (Figure 6A,C).
Paclitaxel treatment of HEY cell-induced xenografts significantly enhanced the expression of
CD31 in tumour cells, compared to untreated controls (Figure 6A,D). However, no difference in the
expression of CD31 was observed in xenografts treated with a combination of paclitaxel and Dasatinib,
compared to paclitaxel only treatment (Figure 6A,D). Dasatinib alone treated group had similar CD31
positive cells in comparison to other treatment groups (Figure 6A,D).
The tyrosine kinase oncoprotein, CD117 (c-Kit) is associated with chemotherapy resistance and
can be used as a predictive CSC marker in ovarian cancer [19,20]. The paclitaxel-treated tumours
expressed significantly greater level of this marker than untreated treated tumours (Figure 6A,E).
However, combining Dasatinib with paclitaxel did not overcome this effect (Figure 6A,E).
Octamer-binding transcription factor 4 (OCT4) is an embryonic stem cell marker, the expression
of which was upregulated in ovarian tumours to enhance cancer cell proliferation, migration and
decreased cisplatin sensitivity [21]. Paclitaxel treatment significantly enhanced OCT4 expression levels
in mouse xenografts (Figure 6A,F). Dasatinib only treatment did not induce a marked change in
OCT4 expression compared to the untreated control group (Figure 6A,F). In paclitaxel and Dasatinib
combined treatment groups, no change in the expression of OCT4 was observed compared to paclitaxel
treated group (Figure 6A,F).
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2.7. Tumours Treated with Dasatinib in Combination with Paclitaxel Had a Reduced Tendency to Invade
Peritoneal Organs and Had Significantly Reduced Mononuclear Infiltrate
Histological analysis of organs revealed that the induced tumours in the control group, were
invasive and appeared to progress through adjacent peritoneal organs. In the liver, some lobes were
completely replaced by tumours with further smaller invading frontal lesions (Figure 7A). Similarly,
in the pancreas exocrine cells were segmented and in some regions were replaced by large tumour
masses. Across all groups, the intestinal tract was the least invaded; however, some mice in the control
group showed attachment and invasion into the muscular layers of the small intestines (Figure 7A).
In the paclitaxel group, cells in the tumours appeared to be more disorganised than other groups.
However, overall there was less penetration into organs, particularly the liver compared to the control
group. On the other hand, the tumours treated with Dasatinib had less leading edges invading into
the liver (Figure 7A). While some regions of the liver had high tumour presence, there were distinct
borders between tumour and liver cells. In this group, there was minimal tumour attachment and
invasion into small intestines. The combination treated tumours also revealed a reduced tendency for
invasion into organs, particularly liver and pancreas.
In addition, the livers and tumours of mice treated with paclitaxel appeared necrotic with fibrosis
and were surrounded by mononuclear cell infiltrates (F4/80 staining). Similar pattern of mononuclear
cell infiltration was observed in tumours of control mice but to a less significant degree (Figure 7B).
Mononuclear cell infiltration in Dasatinib and the combination treatment groups was significantly less
than in the paclitaxel-treated group.
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2.8. Termination of Paclitaxel, Dasatinib or a Combination of Both Treatments Resulted in Robust Tumour
Development with no Change in Survival of Tumour Bearing Mice
In this experiment, mice were treated as described above until endpoint was reached by the
control group, at which time treatment in all other groups was stopped. The survival period in mice
were noted following termination of paclitaxel, Dasatinib or combination treatments, until the endpoint
was reached by each individual animal. Overall, there was no significant difference in the survival of
mice within groups treated with paclitaxel, Dasatinib and combination of the two (Figure 8).
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3. Discussion
In this study, we report significantly high expression of phosphorylated Src in high-stage ovarian
tumours compared to normal/benign and low-stage ovarian tumours. Src overexpression has been
reported in various cancers, including ovarian cancer, during the progressive stages and is known
to promote cancer cell survival and growth leading to poor survival in patients [22,23]. We also
demonstrate that ascites-derived tumour cells, isolated from chemotherapy-treated recurrent ovarian
cancer patients, have significantly high expression of activated Src compared to ascites-derived tumour
cells of chemonaïve patients. This suggests that activated Src may have a potential role in facilitating
chemoresistance which is associated with recurrence in ovarian cancer. Given that Src signalling has
been previously implicated in promoting chemoresistance in ovarian cancer [13,23,24], in the present
study we aimed to investigate the CSC-mediated anti-tumour activity of Dasatinib, alone and in
combination with paclitaxel in vitro and in vivo.
Paclitaxel is a commonly used chemotherapeutic agent in ovarian cancer patients, however, some
advanced-stage patients can present a high degree of paclitaxel resistance [25,26]. In this study, we
show an upregulation of phophorylated Src in response to paclitaxel in two ovarian cancer cell lines
in vitro. This upregulation was concomitant with a significant increase in the expression of CSC-like
markers following paclitaxel treatment compared to untreated control cells. This suggests a potential
association between the paclitaxel-induced activation of Src pathway and the emergence of CSC-like
properties in ovarian cancer. We have previously reported emergence of CSCs in response to paclitaxel
treatment in ovarian cancer cell lines and in vivo tumour xenografts induced either by intraperitoneal
injection of ovarian cancer cells pre-treated with paclitaxel in vitro [27], or in response to paclitaxel
treatment after ovarian cancer cells were injected intraperitoneal in mice [18,28]. These results support
the theory that paclitaxel treatment of ovarian cancer cells provokes an escalation of CSC-like resistant
progenies in residual ovarian tumour populations, which hypothetically may use the activated Src
pathway to evade cytotoxic effects of the chemotherapy. In this context, targeting the CSC population
through Src inhibition may provide an effective approach to overcome CSC-mediated chemoresistance.
Recently, combination therapies that include a CSC-specific targeted agent and a non-CSCs-targeted
agent such as chemotherapy, were suggested to be the most effective approach in the treatment of
cancer [29].
Dasatinib is a dual Src/Abl kinase inhibitor that has been shown to possess anti-tumour activity
in a number of solid tumours [30,31]. We studied the effect of Dasatinib in an intraperitoneal model of
ovarian cancer metastasis, which mimics human progression of the disease. The tumour burden of
untreated control mice was significantly higher than paclitaxel-alone and the combination of paclitaxel
and Dasatinib treated groups. As expected, paclitaxel treatment reduced the burden by approximately
half compared to the control group. However, Dasatinib in combination with paclitaxel had no
additional effect in further decreasing the paclitaxel-reduced tumour burden. There were indications
that paclitaxel-treated tumours had acquired an aggressive phenotype. Firstly, the cells comprising
the tumours of paclitaxel treated mice were largely positive for p-Src. This upregulation of the active
Src pathway may have benefited paclitaxel treated surviving cells in mouse tumours by allowing
rapid renewal and survival, as indicated by the greater number of Ki67 positive cells found in these
xenografts. Additionally, the paclitaxel treated tumours had high expression levels of CSC markers
(CD117 and OCT4) and a significantly greater expression of tumourigenic CA125 and vascularisation
marker CD31.
Dasatinib treatment alone appeared to impact tumour viability with reduced number of Ki67
positive proliferating cells, compared to paclitaxel treatment. However, combination treatment did not
significantly suppress the paclitaxel-effect as Ki67 staining of these tumours remained significantly
higher than control and Dasatinib-treated tumours. Dasatinib combined with paclitaxel had no
significant effect on the paclitaxel-induced upregulation of CA125, CD117, OCT4 and CD31. Hence,
Dasatinib in combination with paclitaxel did not significantly overcome the proliferative, tumourigenic,
vasculogenic and CSC-like effect of paclitaxel in HEY cell induced ovarian tumours. However, mice
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administered with Dasatinib in combination with paclitaxel, lacked intensive invasion into pancreas
and liver, major organs affected by ovarian tumour metastasis, suggesting that Dasatinib may hold
some potential in targeting intra-peritoneal dissemination of ovarian cancer.
A cancer-rich inflamed microenvironment results in the recruitment of monocyte-macrophage
lineage cells, which promote tumour growth and progression of cancers via release of cytokines
and chemokines. The inflammatory environment also increases the frequency of regulatory T cells
(Tregs) that assists immune evasion of cancer cells through T-cell suppression and activation [32].
High macrophage counts are associated with a poor prognosis in a number of cancers, including
cervical, endometrial, prostate, lung, pancreatic cancers and glioblastomas [33]. Furthermore,
macrophages have been shown to trigger therapy resistance by promoting signalling pathways in
cancer cells [34]. In our study, we identified increased infiltration of F4/80 stained mouse macrophages
in paclitaxel treated tumours compared to control tumours. As treatment with chemotherapy induces
an inflammatory secretory DNA damage response in surviving cells, the infiltration of mouse
macrophages in these tumours was not unexpected [35]. This infiltration of macrophages was reduced
in Dasatinib-treated tumours. As such, inhibition of Src signalling in addition to suppression of
infiltrating macrophages may be part of the mechanisms underlying Dasatinib-driven reduced tumour
burden and invasion observed in our study [36]. Src family of kinases play a crucial role in myeloid
cell recruitment and one of the side effects listed for Dasatinib in humans is the suppression of
myeloid-derived cell infiltration [36]. However, immune cell infiltration and its potential in promoting
or suppressing tumour progression is a subject of further investigation in future ovarian cancer studies.
Src kinases forms part of a large family of non-receptor tyrosine kinases that regulate a number
of signaling pathways that impact on the behavior of tumour cells, including proliferation, survival,
migration, invasion, and angiogenesis [37–40]. Src inhibitors (Dasatinib, saracatinib, bosutinib, etc)
have been in clinical development, but their efficacy in clinical trials has not been adequate. In addition,
as this vast family of tyrosine kinase regulate multiple functions in tumours, inhibition of specific
members of Src family of kinases may not have the functional outcome due to compensatory increase
in other members of the family [41]. Moreover, Src kinases play an important role in the development
of host immune responses; such as the development and activation of T lymphocytes, natural killer
cells, macrophages and dendritic cells, which are enhanced by increased expression or activation of Src
kinases [42]. Hence, it can be suggested that the use of Src inhibitors in the treatment of cancers may
inhibit host immune mechanisms against cancer cells and may render patients vulnerable to infections.
Such adverse effects of Src inhibitors on host immunity has been shown for leukemia patients and
emphasizes the need for use of Src inhibitors with caution [43].
4. Materials and Methods
4.1. Human Ethics Approval
This research project was approved by the Human Research and Ethics Committee (HREC
approval #09/09) of The Royal Women’s Hospital, Melbourne, Australia. Human samples were
obtained from patients undergoing treatment at The Royal Women’s Hospital after obtaining written
consent under protocols approved by the Human Ethics approval #09/09.
4.2. Human Primary Tissue Collection and Preparation
Primary ovarian tissues were obtained from patients requiring surgery at the Oncology Dysplasia
Unit of The Royal Women’s Hospital, Melbourne, Australia. The histopathological diagnosis, including
tumour grade and stage were determined by independent pathologists at The Royal Women’s Hospital,
Melbourne, Australia as part of the clinical diagnosis. Normal ovarian tissue samples were obtained
from women undergoing total abdominal hysterectomy or bilateral salpingo-oophorectomy due to
pre-diagnosed medical conditions. Benign tissue samples were obtained from patients who were
presented with benign ovarian cysts and required laparotomy. Patients treated with chemotherapy,
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immunotherapy or radiation prior to surgery was omitted from this study. At the time of collection,
tissue samples were fixed in 4% paraformaldehyde, or snap frozen in liquid nitrogen and stored at
−80 ◦C.
4.3. Human Ascites Collection
Human ascites samples were collected from patients diagnosed with advanced-stage (FIGO stages
III–IV) serous ovarian carcinoma, and adenocarcinoma Not Otherwise Specified (NOS). Samples were
collected during debulking surgery and before the commencement of any chemotherapy treatment
(termed chemonaïve), or at the time of disease recurrence by paracentesis where patients were not all
treated identically but had previously received combinations of chemotherapies (termed chemotherapy
treated). The samples were processed for the isolation of ascites-derived tumour cells as we have
described previously [44]. Briefly, on the day of collection, ascetic fluid samples were centrifuged at
1200 rpm for 5 min at room temperature, and the supernatant was discarded. Contaminating red blood
cells in the cell pellet of ascites were removed by hypotonic lysis and centrifuged at 1200 rpm for 5 min
at room temperature. After discarding the supernatant, the bulk of the ascites cells were resuspended
in a 1:1 ratio of MCDB 131 (Thermo Fisher, Scoresby, Australia) and DMEM (Sigma-Aldrich, St. Louis,
MO, USA) supplemented with 10% (v/v) heat inactivated FBS (Thermo Fisher Scientific, Waltham,
MA, USA), 2 mM L-glutamine (MCRI), and 1% (v/v) penicillin and streptomycin (MCRI), then seeded
onto Costar®6 well clear flat bottom ultra-low attachment multiwall plates or Corning®ultra-low
attachment culture 100 mm petri dishes (Corning Incorporated, NY, USA). The ascites cells were
incubated at 37 ◦C with 5% CO2 and grown as either non-adherent spheroid cells or adherent cells
before collection within a week. Images of the collected ascites cells were captured using the Axiovert
100 phase contrast microscope (Zeiss, Oberkochen, Germany) and viewed using the DeltaPixView
Software (https://www.deltapix.dk/software.html).
4.4. Cell Cultures
Ovarian serous carcinoma HEY cells (representative of Type II tumour) was obtained from
Dr. Georgia Chenevix-Trench, Queensland Institute for Medical Research, Australia and has been
described previously [18,28]. The cells were maintained in complete RPMI 1640 (Sigma-Aldrich,
Sydney, Australia) supplemented with 10% (v/v) foetal bovine serum (Thermo Fisher Scientific), 2 mM
L-glutamine (Murdoch Childrens Research Institute, Victoria, Australia) and 1% (v/v) penicillin and
streptomycin (MCRI). Cells were maintained under standard culture conditions in 5% carbon dioxide
infused incubators at 37 ◦C.
4.5. Drug Preparation
Paclitaxel (Hospira Australia, Melbourne, Victoria, Australia) was directly dissolved in respective
complete growth medium to concentrations ranging from 0.0005–1 µg/mL. Dasatinib (Bristol Myers
Squibb, New York, NY, USA) was dissolved in dimethyl sulfoxide (DMSO) ReagentPlus®, ≥99.5%
(Sigma-Aldrich) and was either stored at −80 ◦C for 6 months, or dissolved in complete growth media
for cell treatment to concentrations ranging from 1–50 µM. All drugs dissolved in complete growth
media were prepared the day before and stored at 4 ◦C prior to treating cells.
4.6. Chemosensitivity Assay
Cells (2.5× 104) were seeded in triplicate in 96 well plates and incubated overnight under standard
conditions. The following day, the media was discarded and replaced with various concentrations
of paclitaxel [18], Dasatinib and combination treatments. After a 48 h incubation, the media was
replaced with 100 µL of thiazolyl blue tetrazolium (MTT) solution (Sigma-Aldrich) dissolved in
1× PBS to a final concentration 0.5 mg/mL and incubated for 2 h at 37 ◦C with 5% CO2. The MTT
reagent was then discarded and replaced with 100 µL of DMSO, and the plate was read at OD-595
nm using the SpectraMax190 Absorbance Microplate Reader and SoftMax®Pro Computer Software
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(https://www.moleculardevices.com). The average of each triplicate was expressed as the percentage
of the average viable cells relative to untreated control cells.
4.7. Antibodies and Reagents
Polyclonal antibody against phosphorylated Src (p-Src) (Tyr416), total Src (t-Src), EpCAM and
CD117 (c-Kit) were obtained from Cell Signalling Technology (Beverly, MA, USA). Monoclonal
antibody against CD133 was obtained from Miltenyl Biotec (Macquarie Park, NSW, Australia).
Antibodies against Ki67, CA125, OCT3/4 CD117 (c-Kit) and CD31 used for immunohistochemistry
were obtained from Ventana (Roche, Basel, Switzerland).
4.8. Cell Preparation for Immunofluorescence
This was performed by the method described previously [18]. Viable cell numbers were
determined using Trypan Blue. A concentration of 1 × 103 for a cell line and 100–200 µL of
non-adherent ascites-derived cells were seeded in an 8-well NuncTM Lab-TekTM Chamber SlideTM
System (Thermo Fisher Scientific) under standard conditions, until the cells reached 60% confluence.
The growth medium was discarded, and replaced with fresh complete growth medium, or medium
containing paclitaxel, Dasatinib or the combination. Cells were incubated again for a defined period
as per experiment. Cells were fixed in 4% paraformaldehyde, and then blocked with CAS-BlockTM
Histochemical Reagent (Thermo Fisher Scientific) for 10 min as per manufacturer’s instructions,
followed by an overnight incubation at 4 ◦C with respective primary antibodies. After 2 washes with
1× PBS, cells were probed with Alexa Fluor®488 conjugated Goat anti-Mouse antibody or Donkey
anti-Goat, or Alexa Fluor®568 conjugated Goat anti-Rabbit secondary antibodies at a 1:200 for 2 h at
room temperature in the dark. 4’,6-diamidino-2-phenylindole (DAPI) (Life Technologies) was used to
counter stained cells at a 1:50000 dilution for 5 min before mounting the slides with 80% glycerol and
secured with coverslips.
Fluorescence imaging was visualized and captured using an Olympus CellR fluorescent
microscope and associated software (Olympus Corporation, Tokyo, Japan). The CellR software has
inbuilt analysis parameters that was set up at equal intensity all the time to avoid biased measurements.
Semi-quantitative analysis was performed using the ImageJ software to assess the fluorescent intensity
of individual staining per cell as published previously [18]. The results are expressed as a percentage
of fold change of the protein of interest for each sample.
4.9. Western Blotting
This was performed as described previously [28]. After the cells were treated with paclitaxel,
Dasatinib or the combination, protein was harvested (triplicates/group) using RIPA buffer
supplemented with 2 mM sodium orthovanadate (Na3VO4), 2 mM phenylmethylsulfonyl fluoride
(PMSF) and 1 mg/mL aprotonin (Sigma-Aldrich) and samples sonicated at an amplitude of 40 for
15 secs, using a Microson Ultrasonic cell disrupted (Misonic Incorporated, NY, USA). The extracted
protein was quantified using the Quick StartTM Bradford Protein Assay Reagent Kit (Bio-Rad, Hercules,
CA, USA). Samples were diluted to 40–50 µg in a 95:5 ratio of 2× Laemmli sample buffer (Bio-Rad)
and β-mercaptoethanol (Sigma-Aldrich) and loaded into each well, with the pre-stained SDS-PAGE
Precision Plus ProteinTM Kaleidoscope Standards (Bio-Rad) as a standard ladder. Electrophoresis was
performed using a Mini-Protean II Electrophoresis Cell (Bio-Rad Laboratories) and transferred on
to polyvinylidene fluoride or nitrocellulose membranes. The membranes were incubated in Super
Signal®western blot Enhancer (Thermo Fisher Scientific) then blocked with 5% (w/v) BSA1 h at room
temperature. Primary antibodies were applied for 48 h at 4 ◦C in the presence of SuperSignal®Diluent
(Thermo Fisher Scientific), then probed with the secondary antibodies for 2 h at room temperature and
visualised using SuperSignalTM West Pico Chemiluminescent Substrate (Thermo Fisher Scientific) and a
Fuji Film Las-4000 with associated software (GE Healthcare, Buckinghamshire, UK). Semi-quantitative
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densitometry analysis was performed using ImageJ software after standardisation to housekeeping
GAPDH (Imgenex, San Diego, CA, USA).
4.10. Flow Cytometry
This was performed as we have described previously [18,45]. A cell pellet containing ~105 cells
per 200 µL was resuspended in 1× PBS and incubated with primary antibody with or without
phycoerythrin (PE)-conjugated for 1 h at 4 ◦C. For non-PE-conjugated primary antibodies, cells were
washed with 1× PBS, collected by centrifugation at 1200 rpm at 4 ◦C for 5 mins, and followed by
two more washing process before incubating with PE-conjugated goat anti-mouse IgG monoclonal
antibody (1:100) for 20–30 min at 4 ◦C. Cells were then washed with 1× PBS, centrifuged at 1200 rpm
at 4 ◦C for 5 mins, and followed by two more washing process before the cell pellet was resuspended
in 200 µL of 1× PBS. Cells were assayed using FACScan analytical flow cytometer (BD Biosciences,
Franklin Lakes, NJ, USA) and data was analysed using the Cell QuestTM software (BD Biosciences).
The protein expression was measured using the Geo Mean value of the cell surface marker of interest
relative to the IgG Geo Mean value used as a negative control. Results were expressed as the mean of
cell fluorescent intensity shown as a histogram.
4.11. Mouse Experiments
Animal Ethics: This study was performed in strict accordance with the recommendations in the
Guide for the Care and Use of the Laboratory Animals of the National Health and Medical Research
Council of Australia. The experimental protocol was approved by the Department of Surgery, Royal
Melbourne Hospital and University of Melbourne’s Animal Ethics Committee (Project-1413207.1).
4.12. Intraperitoneal Ovarian Cancer Model-Treatment Regimen
These experiments were performed as we have described previously [18,27]. Female Balb/c
nu/nu mice (age 6–8 weeks) were obtained from the Animal Resources Centre, Western Australia
and were housed in a standard pathogen-free environment with access to food and water. Viable
cells (5 × 106) were injected intraperitoneally (i.p) into each mouse. After 19 days, mice received
weekly i.p injection of paclitaxel (15 mg/kg of mice body weight) and daily oral gavages of Dasatinib
(10 mg/kg of mice bodyweight) (n = 5/group). Animals were euthanized at day 12 after starting
treatment (Figures 5–7). Organs (such as liver, kidney, gastrointestinal tract, pancreas and spleen)
and solid tumours were collected and processed for H&E and/or immunohistochemical analysis.
Endpoint criteria included loss of body weight exceeding 15% of initial body weight and general
patterns of diminished wellbeing such as abnormalities in respiration, motility, posture, and response
to provocation.
In another set of experiments, 19 days post-i.p injection with HEY cells, mice were divided into
three groups based on the treatment given: paclitaxel, Dasatinib, and a combination of paclitaxel and
Dasatinib (n = 5/group). All treatments were terminated when control mice reached the endpoint
(as described above). Survival of individual mice was monitored with remaining animals until they
reached endpoint (Figure 8).
4.13. Processing of Mice Tissues
Formalin-fixed mice organs and resected tumours were paraffin embedded by staff at the
Anatomical Pathology Laboratory Services, The Royal Children’s Hospital, Melbourne, Australia.
The tissues samples were dehydrated in 70% ethanol (2 h) and 90% ethanol (1 h) solutions before being
immersed in xylene (2 h) and embedded in paraffin wax for 2 h.
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4.14. Haematoxylin and Eosin Stain (H&E Stain)
H&E staining of mouse organs and tumours was performed by the staff at the Anatomical
Pathology Laboratory Services located at The Royal Children’s Hospital, Melbourne, Australia
according to the standard H&E protocol as described previously [28]. Paraffin embedded tissues
were sectioned at 4 µm thickness, deparaffinised, rehydrated and stained for 3 min with Haematoxylin
(Australian Biostain Pty Ltd, Traralgon, VIC, Australia). Slides were rinsed with 0.25% Acid Alcohol
and Scott’s Tap water Substitute. Sections were stained with Eosin (Amber Scientific, Midvale, WA,
Australia) for 2 min before final rinsing with absolute alcohol and xylene. The metastatic development
was assessed by a qualified pathologist at The Royal Women’s Hospital (Melbourne, VIC, Australia).
Histological images of stained organs and tumours were taken using Evos FL Auto 2 microscope
(Thermo Fisher Scientific).
4.15. Immunohistochemical Analysis
Formalin-fixed, paraffin embedded 4 µm sectioned patient samples and mouse tumour xenografts
were stained using a Ventana Benchmark Immunostainer (Ventana Medical Systems, Inc. Tucson,
AZ, USA) as described previously [18,28]. Tumour sections were de-waxed with Ventana EZ Prep
and endogenous peroxidise activity blocked using the Ventana Universal DAB inhibitor. Primary
antibodies against p-Src, t-Src, Ki67, CA125, Oct4, CD117 (c-kit), CD133 and CD31 were diluted
as per manufacturer’s instructions. The sections were counter-stained with Ventana Haematoxylin
and Blueing solution, and primary antibody staining was detected using the ultra-View Universal
DAB detection Kit (Roche, Basel, Switzerland). Negative controls were prepared by incubating each
tumour sections without primary antibodies. Immunohistochemistry images were taken using an
Evos FL Auto 2 microscope (Thermo Fisher Scientific). DAB staining (5× 200 µm images/section)
was quantified using processing packages in ImageJ (positive pixels or number of positive cells) and
Aperio (strong positive staining pixel count). Quantification was standardised to area and normalised
to the negative control sections. Results displayed as mean ± SD.
4.16. Statistical Analysis
Welch’s t-test was used for the statistical analyses of all biological assays involving comparison
between two groups. Comparisons between two groups with more than one independent variable
were analysed using Two-Way ANOVA with Bonferroni’s post hoc test. Comparisons between more
than two groups to designated control groups were analysed using One-Way ANOVA with Dunnett’s
post hoc test. Comparisons between more than two groups with one independent variable were
analysed using One-Way ANOVA with Tukey’s post hoc test. Comparisons of survival curves were
analysed using Kaplan-Meier curves with Log-rank test. Each experiment was performed a minimum
of three replicates using a minimum of three biological samples. Data was analysed using Microsoft
Excel 2010 and GraphPad Prism Software (version 6).
5. Conclusions
In summary, we have shown that Src is significantly activated in high-stage ovarian tumours.
Phosphorylated Src is also upregulated in response to chemotherapy treatment in ascites-derived
patient’s tumour cells and in vitro ovarian cancer cells. As such, Src expression appears to correlate
with chemoresistance and may contribute to subsequent recurrence and mortality in ovarian cancer
patients, making it an appealing potential target in emerging therapeutic options. However, in this
study, suppressing Src activation using multi-kinase inhibitor Dasatinib, only partially overcomes
paclitaxel-induced effects in cells and tumours. Dasatinib appears to be limited in modulating
paclitaxel-induced proliferative, tumourigenic, vasculogenic and CSC-mediated effects in ovarian
cancer. This is supported by insignificant changes in Ki67, CA125, CD31, CD117 and OCT4 expression
in combined paclitaxel and Dasatinib tumours, compared to paclitaxel-alone treated xenografts.
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In addition, Dasatinib lacks the ability to prolong disease-free progression in paclitaxel-induced
tumours. This suggests that Src activation may not be the primary target in paclitaxel induced
CSC-mediated chemoresistance and recurrence in ovarian cancer. A recent study has shown
that simultaneous addition of Src inhibitors with paclitaxel may not be ideal for cancer control;
however, sequential addition of Src inhibitor after paclitaxel treatment may overcome the adaptive
paclitaxel-induced chemoresistance changes making resistant cells sensitive to dual therapy [46].
This approach, if reproducible, allows exploiting the adaptive changes induced in cancer cells by
chemotherapy before they can be made susceptible to Src inhibitors. Studies like that warrant further
investigation for future clinical trials on Src inhibitors.
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